View More Recent Stories

Aug 31, 2017 09:10AM VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
Aug 21, 2017 09:00AM VistaGen Therapeutics Expands VistaStem's Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD
Aug 14, 2017 04:05PM VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update
Aug 8, 2017 08:42AM VistaGen Therapeutics (VTGN) Receives Notice of Allowance For Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells
Aug 8, 2017 08:30AM VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potentia
Jul 10, 2017 08:30AM VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain
Jun 29, 2017 08:30AM VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update
Jun 22, 2017 08:32AM VistaGen Therapeutics (VTGN) Reports Peer-Reviewed Publication Highlighting AV-101's Excellent Safety Profile & Potential Non-Opioid Treatment for Neuropathic Pain
Jun 22, 2017 08:30AM VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neurop
May 1, 2017 08:00AM VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement
Apr 27, 2017 09:00AM VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain
Mar 29, 2017 09:02AM VistaGen Therapeutics (VTGN) Says EPO to Grant European Patent for AV-101
Mar 29, 2017 09:00AM VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101
Mar 10, 2017 03:17PM VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell
Mar 8, 2017 09:00AM VistaGen Therapeutics to Ring the Nasdaq Stock Market Closing Bell on Monday, March 13, 2017
Feb 13, 2017 04:15PM VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update
Jan 5, 2017 09:33AM VistaGen Therapeutics to Present at Biotech Showcase™ 2017
Dec 14, 2016 07:05AM VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics
Nov 30, 2016 07:05AM VistaGen Therapeutics to Present at 9th Annual LD Micro Main Event
Nov 14, 2016 04:15PM VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update
Oct 4, 2016 07:00AM VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations
Sep 22, 2016 08:05AM VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones
Jun 20, 2016 08:01AM VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
May 16, 2016 01:40PM VistaGen Completes $10 Million Public Offering
View More Recent Stories